Medco (NYSE: MHS) Reports 13.5 Percent Rise in 3Q Profits
Rochester, New York 11/04/2009 02:40 AM GMT (TransWorldNews)
Medco Health Solutions Inc. (NYSE: MHS) said Tuesday its profit rose 13.5 percent as the company gained new clients and benefited from price inflation of brand-name drugs, according to Associated Press.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Medco, the largest U.S. pharmacy benefits manager, makes larger profits on sales of generic drugs, although they bring in less revenue. With a large wave of blockbuster drugs going off-patent in 2011, drugmakers have gotten more aggressive about raising their prices recently, which is also helping Medco.
Medco Chairman and CEO David Snow said the recession motivated health plan sponsors and members to look for ways to save money, which helped the company's business. But the desire for savings will remain as the economy improves, he said.
The company earned $335.6 million, or 69 cents per share, up from $295.7 million, or 58 cents per share, a year prior. Excluding charges, the company said it earned 75 cents per share. Revenue surged 18 percent to $14.79 billion from $12.56 billion.
Analysts polled by Thomson Reuters expected earnings of 72 cents per share on $14.68 billion in revenue.
Medco shares rose $1.51, or 2.6 percent, to $59.09 in midday trading after rising to an all-time high of $59.69 earlier inn the day.
Medco, headquartered in Franklin Lakes, N.J., said adjusted prescriptions increased 14 percent to 220.2 million. That includes 144.3 million prescriptions filled in drugstores, up 25 percent from a year ago. Mail order volumes decreased because demand for brand-name drugs has fallen during the recession. Mail delivery of generic drugs remained strong, Medco said.
Revenue from Medco's Accredo specialty pharmacy business rose 19 percent to $2.4 billion. The generic dispensing rate, or the portion of prescriptions that were filled using low cost generic drugs, rose to 67.7 percent from 64.4 percent.
The company slightly raised its 2009 profit outlook to between $2.80 and $2.82 per share from a range of $2.76 to $2.81 per share. The new forecast is mainly above Wall Street forecasts of $2.80 per share.
Looking ahead, the company set 2010 profit guidance between $3.28 and $3.38 per share. Analysts expect $3.28 per share. Medco expects to earn 25 cents per share for the year from sales of generic drugs, as top sellers like Effexor XR, Flomax, and Aricept lose patent protection. That's almost double the 13 cents per share it expects in 2009.
Snow said Medco expects to retain 99 percent of its clients in 2010, and has gained $4 billion in new contract revenue for the year.
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
staff@pennystockprofessor.com
www.pennystockprofessor.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
Penny Stock Professor
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
